Daiichi is a pharmaceutical company that specializes in the research, development, and manufacturing of innovative medicines and healthcare products.
Daiichi was founded in 1899 as Daiichi Kogyo Seiyaku Co., Ltd.
In 1985, the company changed its name to Daiichi Pharmaceutical Co., Ltd.
In 2005, Daiichi Pharmaceutical merged with Sankyo Co., Ltd. to form Daiichi Sankyo Company, Limited.
Daiichi Sankyo expanded its global presence through various acquisitions and partnerships in the following years.
The company focuses on therapeutic areas such as cardiovascular, oncology, and rare diseases.
Daiichi Sankyo is committed to improving patients' lives through innovative treatments and medical solutions.
Pfizer is a global pharmaceutical company known for its wide range of prescription drugs, vaccines, and consumer healthcare products.
Novartis is a multinational pharmaceutical company that develops and manufactures a broad range of healthcare products, including innovative prescription drugs and generics.
Merck & Co., known as MSD outside the United States and Canada, is a leading global pharmaceutical company that focuses on developing innovative medicines, vaccines, and animal health products.
Daiichi Sankyo has various innovative cancer treatments, including targeted therapies and immunotherapies, to fight different types of cancer.
Edoxaban is an oral anticoagulant developed by Daiichi Sankyo for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Cariprazine is an atypical antipsychotic developed by Daiichi Sankyo for the treatment of schizophrenia and bipolar disorder.
Daiichi Sankyo specializes in the research, development, and manufacturing of innovative medicines and healthcare products, with a focus on therapeutic areas such as cardiovascular, oncology, and rare diseases.
Daiichi was founded in 1899 as Daiichi Kogyo Seiyaku Co., Ltd.
Pfizer, Novartis, and Merck & Co. are some of the competitors of Daiichi in the pharmaceutical industry.
Daiichi has a diverse range of products, including its cancer portfolio, edoxaban (LIXIANA) for stroke prevention, and cariprazine (Vraylar) for schizophrenia and bipolar disorder treatment.
Daiichi Sankyo is committed to improving patients' lives through innovative treatments and medical solutions.
